115 related articles for article (PubMed ID: 25468650)
1. Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts.
Fuller M; Mellett N; Hein LK; Brooks DA; Meikle PJ
Mol Genet Metab; 2015 Feb; 114(2):268-73. PubMed ID: 25468650
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation impact on Fabry disease.
Di Risi T; Vinciguerra R; Cuomo M; Della Monica R; Riccio E; Cocozza S; Imbriaco M; Duro G; Pisani A; Chiariotti L
Clin Epigenetics; 2021 Feb; 13(1):24. PubMed ID: 33531072
[TBL] [Abstract][Full Text] [Related]
3. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
4. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders.
Seras-Franzoso J; Díaz-Riascos ZV; Corchero JL; González P; García-Aranda N; Mandaña M; Riera R; Boullosa A; Mancilla S; Grayston A; Moltó-Abad M; Garcia-Fruitós E; Mendoza R; Pintos-Morell G; Albertazzi L; Rosell A; Casas J; Villaverde A; Schwartz S; Abasolo I
J Extracell Vesicles; 2021 Mar; 10(5):e12058. PubMed ID: 33738082
[TBL] [Abstract][Full Text] [Related]
5.
Li P; Xi Y; Zhang Y; Samad A; Lan W; Wu Y; Zhao J; Chen G; Wu C; Xiong Q
Cells; 2024 Mar; 13(5):. PubMed ID: 38474401
[TBL] [Abstract][Full Text] [Related]
6. Elevated interleukin-8 expression by skin fibroblasts as a potential contributor to pain in women with Fabry disease.
Hofmann L; Grüner J; Klug K; Breyer M; Klein T; Hochheimer V; Wagenhäuser L; Wischmeyer E; Üçeyler N
PLoS One; 2024; 19(4):e0300687. PubMed ID: 38593151
[TBL] [Abstract][Full Text] [Related]
7. Endothelial Cell Dysfunction and Hypoxia as Potential Mediators of Pain in Fabry Disease: A Human-Murine Translational Approach.
Klug K; Spitzel M; Hans C; Klein A; Schottmann NM; Erbacher C; Üçeyler N
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895103
[TBL] [Abstract][Full Text] [Related]
8. Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations.
Izhar R; Borriello M; La Russa A; Di Paola R; De A; Capasso G; Ingrosso D; Perna AF; Simeoni M
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254927
[TBL] [Abstract][Full Text] [Related]
9. Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients.
Keslová-Veselíková J; Hůlková H; Dobrovolný R; Asfaw B; Poupetová H; Berná L; Sikora J; Golán L; Ledvinová J; Elleder M
Virchows Arch; 2008 Jun; 452(6):651-65. PubMed ID: 18351385
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-based GLA knockout to generate the female Fabry disease human induced pluripotent stem cell line MHHi001-A-15.
Juchem M; Lehmann N; Behrens YL; Bär C; Thum T; Hoepfner J
Stem Cell Res; 2024 Jun; 79():103478. PubMed ID: 38905814
[TBL] [Abstract][Full Text] [Related]
11. Inflammation and Exosomes in Fabry Disease Pathogenesis.
Coelho-Ribeiro B; Silva HG; Sampaio-Marques B; Fraga AG; Azevedo O; Pedrosa J; Ludovico P
Cells; 2024 Apr; 13(8):. PubMed ID: 38667269
[TBL] [Abstract][Full Text] [Related]
12. FDrisk: development of a validated risk assessment tool for Fabry disease utilizing electronic health record data.
Lobel CJ; Laney DA; Yang J; Jacob D; Rickheim A; Ogg CZ; Clynes D; Dronen J
J Rare Dis (Berlin); 2024; 3(1):2. PubMed ID: 38187171
[TBL] [Abstract][Full Text] [Related]
13. The Fabry cardiomyopathy - diagnostic approach and current treatment.
Weidemann F; Ertl G; Wanner C; Krämer J
Curr Pharm Des; 2015; 21(4):473-8. PubMed ID: 25483948
[TBL] [Abstract][Full Text] [Related]
14. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.
Ferreira S; Ortiz A; Germain DP; Viana-Baptista M; Caldeira-Gomes A; Camprecios M; Fenollar-Cortés M; Gallegos-Villalobos Á; Garcia D; García-Robles JA; Egido J; Gutiérrez-Rivas E; Herrero JA; Mas S; Oancea R; Péres P; Salazar-Martín LM; Solera-Garcia J; Alves H; Garman SC; Oliveira JP
Mol Genet Metab; 2015 Feb; 114(2):248-58. PubMed ID: 25468652
[TBL] [Abstract][Full Text] [Related]
15. Cerebrovascular involvement in Fabry disease: current status of knowledge.
Kolodny E; Fellgiebel A; Hilz MJ; Sims K; Caruso P; Phan TG; Politei J; Manara R; Burlina A
Stroke; 2015 Jan; 46(1):302-13. PubMed ID: 25492902
[No Abstract] [Full Text] [Related]
16. Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement.
Fledelius HC; Sandfeld L; Rasmussen ÅK; Madsen CV; Feldt-Rasmussen U
Acta Ophthalmol; 2015 May; 93(3):258-64. PubMed ID: 25487570
[TBL] [Abstract][Full Text] [Related]
17. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
[TBL] [Abstract][Full Text] [Related]
18. Raynaud's phenomenon associated with Fabry disease.
Germain DP; Atanasiu OI; Akrout-Marouene J; Benistan K
J Inherit Metab Dis; 2015 Mar; 38(2):367-8. PubMed ID: 25511234
[No Abstract] [Full Text] [Related]
19. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance.
Pica S; Sado DM; Maestrini V; Fontana M; White SK; Treibel T; Captur G; Anderson S; Piechnik SK; Robson MD; Lachmann RH; Murphy E; Mehta A; Hughes D; Kellman P; Elliott PM; Herrey AS; Moon JC
J Cardiovasc Magn Reson; 2014 Dec; 16(1):99. PubMed ID: 25475749
[TBL] [Abstract][Full Text] [Related]
20. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease.
Smid BE; van der Tol L; Biegstraaten M; Linthorst GE; Hollak CE; Poorthuis BJ
J Med Genet; 2015 Apr; 52(4):262-8. PubMed ID: 25596309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
